Add to a list

Inactive Instrument

Sirnaomics Ltd. Stock OTC Markets

SRNA.F

KYG2050P1028

Biotechnology & Medical Research

OTC Markets Traded

Analysts' recommendations: Sirnaomics Ltd.

23-06-20	Nomura Adjusts Sirnaomics' Price Target to HK$67.07 From HK$70.07, Keeps at Buy	MT
23-03-30	Nomura Adjusts Sirnaomics' Price Target to HK$70.07 From HK$107.14, Keeps at Buy	MT
22-04-08	Nomura Adjusts Sirnaomics' Price Target to HK$107.14 From HK$97.54, Keeps at Buy	MT

More recommendations

Press Releases: Sirnaomics Ltd.

03-30	TGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook	AQ
25-09-08	Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines	PR
25-09-02	TGFB Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies	AQ
24-10-04	Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development	PR
24-09-19	Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology	PR

More press releases

Managers and Directors: Sirnaomics Ltd.

Manager	Title	Age	Since
Hong Hui Pan CEO	Chief Executive Officer	48	2024-11-05
Yun Ting Yuen DFI	Director of Finance/CFO	35	2021-08-31
David Evans CTO	Chief Tech/Sci/R&D Officer	63	2008-02-29

Director	Title	Age	Since
Yee Hang Lo BRD	Director/Board Member	50	2025-08-31
Peng Zhang BRD	Director/Board Member	50	2025-07-02
Yu Shan Wong BRD	Director/Board Member	56	2025-02-16

More insiders

Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a multi-targeted siRNA therapeutic advancing clinical development across two oncology indications: squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Its STP707 is an intravenous siRNA therapeutic being evaluated in phase I clinical trial for multiple solid tumors, including colorectal, pancreatic, liver, and metastatic melanoma cancers. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	55.54M 48.79M 45.37M 41.63M 78.22M 5.35B 79.43M 539M 210M 2.63B 209M 204M 9.09B	P/E 2024	-0.67x	P/E 2025	-6.46x
Enterprise Value	51.34M 45.09M 41.94M 38.48M 72.3M 4.94B 73.42M 498M 195M 2.43B 193M 189M 8.4B	EV / Sales 2024	24.1x	EV / Sales 2025	-
Free-Float	75.85%	Yield 2024 *	-	Yield 2025	-

07-21	Sirnaomics Ltd. Announces Establishment of External Scientific Advisory Board	CI
06-29	Ningbo Polypeptide Technology Co., Ltd. announced that it has received funding from Sirnaomics Ltd.	CI
06-25	Sirnaomics' Chair Boosts Shareholding; Shares Slide 4%	MT
06-05	Sirnaomics Ltd. Announces Board and Committee Changes, Effective June 5, 2026	CI
05-25	Sirnaomics to Issue HK$11.4 Million Worth of Shares	MT
05-25	Sirnaomics to issue 2.4 million new shares at HK$4.69 each under general mandate	RE
04-23	Sirnaomics Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-30	Sirnaomics says chairman purchases 38,000 shares at average price HK$5.93 per share	RE
03-27	Sirnaomics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-08	Sirnaomics Completes Partial Share Sale	MT
12-22	Sirnaomics Unit's STP707 Shows Clinical Activity in Phase 1 Cancer Trial; Shares Jump 2%	MT
12-08	Sirnaomics Chairman Boosts Stake; Shares Jump 14%	MT
25-09-07	Sirnaomics to Raise HK$206 Million via Share Subscription	MT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SIRNAOMICS LTD.	-.--%	-.--%	-	-	55.54M
ARGENX SE	+0.93%	+6.97%	+59.60%	+68.35%	57.28B
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+40.64%	+83.42%	54.99B
INSMED INCORPORATED	-0.46%	-1.29%	+2.86%	+428.78%	23.18B
BIONTECH SE	-2.97%	-2.35%	-22.53%	-16.40%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+5.73%	+24.13%	-6.24%	20.46B
GENMAB A/S	-1.34%	+0.51%	+26.03%	-29.41%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	+5.67%	+38.77%	+504.71%	15.67B
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+170.77%	+291.37%	14.46B
EXELIXIS, INC.	-0.50%	-0.98%	+21.43%	+180.07%	13.92B
Average	-0.94%	+1.28%	+40.19%	+167.18%	26.68B
Weighted average by Cap.	-0.87%	+2.10%	+39.70%	+133.49%

	2024	2025
Net sales	1.78M 1.56M 1.45M 1.33M 2.5M 171M 2.54M 17.25M 6.74M 84.18M 6.67M 6.53M 291M	-
Net income	-51.38M -45.13M -41.97M -38.51M -72.36M -4.95B -73.48M -498M -195M -2.43B -193M -189M -8.41B	-14.4M -12.65M -11.76M -10.8M -20.28M -1.39B -20.6M -140M -54.58M -682M -54.07M -52.9M -2.36B
Net Debt	-3.71M -3.26M -3.03M -2.78M -5.23M -357M -5.31M -35.99M -14.06M -176M -13.93M -13.63M -607M	-4.2M -3.69M -3.43M -3.15M -5.92M -405M -6.01M -40.78M -15.93M -199M -15.78M -15.44M -688M

Sirnaomics Ltd. Stock OTC Markets

Stocks

SRNA.F

KYG2050P1028

Biotechnology & Medical Research

Valuation: Sirnaomics Ltd.

Latest news : Sirnaomics Ltd.

Analysts' recommendations: Sirnaomics Ltd.

Press Releases: Sirnaomics Ltd.

Managers and Directors: Sirnaomics Ltd.

Bio Therapeutic Drugs

Financials

Company Profile